Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) just unveiled an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced its unaudited consolidated interim results for the first half of 2025, showing a slight decrease in revenue to RMB 2.79 billion, down 1.3% from the previous year. The company experienced a significant drop in gross profit and profit attributable to equity holders, with declines of 19.0% and 36.4% respectively, indicating financial challenges during this period.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$3.88 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products.
Average Trading Volume: 4,218,343
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.89B
See more insights into 9989 stock on TipRanks’ Stock Analysis page.